Galmed Pharmaceuticals Stock Forward View - Price Action Indicator
| GLMD Stock | USD 0.63 -0.02 -3.08% |
Galmed Pharmaceuticals's price is influenced by both fundamental reality and narrative momentum. This module focuses on narrative momentum - how the current news cycle around Galmed Pharmaceuticals is likely to influence price in the short term.
Under current market conditions, the 14-period RSI for Galmed Pharmaceuticals is 0, signaling extreme oversold conditions. This extreme reading suggests selling pressure has dominated recent sessions and appears to be due for at least a temporary pause.Momentum
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter -0.51 | EPS Estimate Current Year -2.31 | EPS Estimate Next Year -0.85 | Wall Street Target Price 12 | EPS Estimate Current Quarter -0.54 |
The summary frames Galmed Pharmaceuticals' price response to attention shifts and peer coverage.
Galmed Pharmaceuticals after-hype prediction price | $ 0.62 |
This analysis adds an attention layer to forecasting, technical studies, analyst estimates, and earnings views.
Historical Fundamental Analysis of Galmed Pharmaceuticals can be used to cross-verify projections for Galmed Pharmaceuticals. The view supplies historical context for the projection discussion.Galmed Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Galmed price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Galmed using various technical indicators. When you analyze Galmed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Previous Price Action Indicator | Price Action Indicator | Trend |
| 0.015 | -0.03 |
| Check Galmed Pharmaceuticals Volatility | Backtest Galmed Pharmaceuticals | Information Ratio |
Galmed Pharmaceuticals Trading Date Momentum
| On March 13 2026 Galmed Pharmaceuticals was traded for 0.63 at the closing time. The top price for the day was 0.67 and the lowest listed price was 0.62 . The trading volume for the day was 5 K. The trading history from March 13, 2026 did not cause price change. The overall trading delta against the current closing price is 6.35% . |
Price Action Indicator (or PAIN) was developed by Michael B. Geraty and published in 'Futures' magazine in August 1997.
| Compare Galmed Pharmaceuticals to competition |
Other Forecasting Options for Galmed Pharmaceuticals
Any investor evaluating Galmed must grapple with the challenge of interpreting Galmed Pharmaceuticals' price movement accurately. Galmed Stock price charts typically contain substantial noise that can complicate analysis and lead to poor decisions.Galmed Pharmaceuticals Related Equities
The following equities are related to Galmed Pharmaceuticals within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Galmed Pharmaceuticals against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Galmed Pharmaceuticals Market Strength Events
Market strength indicators for Galmed Pharmaceuticals assess how the stock responds to ongoing changes in market conditions and investor sentiment. By monitoring these indicators, investors can identify the most opportune moments to trade Galmed Pharmaceuticals.
| Accumulation Distribution | 373.36 | |||
| Daily Balance Of Power | -0.40 | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 0.65 | |||
| Day Typical Price | 0.64 | |||
| Price Action Indicator | -0.03 | |||
| Period Momentum Indicator | -0.02 |
Galmed Pharmaceuticals Risk Indicators
Risk indicator analysis for Galmed Pharmaceuticals is a critical component of accurate price forecasting and sound investment decision-making. By identifying how much risk is embedded in Galmed Pharmaceuticals' investment, investors can decide how to position and protect their exposure.
| Mean Deviation | 3.85 | |||
| Standard Deviation | 4.9 | |||
| Variance | 24.03 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Galmed Pharmaceuticals
Coverage intensity for Galmed Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Galmed Pharmaceuticals Short Properties
Short sentiment tied to Galmed Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 930.8 K | |
| Cash And Short Term Investments | 15.3 M |
More Resources for Galmed Stock Analysis
A comprehensive view of Galmed Pharmaceuticals starts with financial statements and ratio context. Ratio context helps frame profitability, efficiency, and growth trends for Galmed Pharmaceuticals Stock. Selected reports below provide context for Galmed Stock:Historical Fundamental Analysis of Galmed Pharmaceuticals can be used to cross-verify projections for Galmed Pharmaceuticals. The view supplies historical context for the projection discussion. Before investing in Galmed Stock, review our How to Buy Galmed Pharmaceuticals guide for key considerations.Analysis related to Galmed Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Understanding Galmed Pharmaceuticals includes distinguishing between market value and book value, where book value reflects Galmed's accounting equity. Galmed Pharmaceuticals' market capitalization is 4.15 M. A P/B ratio of 0.22 suggests Galmed Pharmaceuticals trades near or below book value. Intrinsic value reflects what Galmed Pharmaceuticals' fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish Galmed Pharmaceuticals' value from its trading price, which are computed with different methods. For Galmed Pharmaceuticals, key inputs include a P/B ratio of 0.22, and ROE of -46.34%. The quoted price is simply the exchange level where supply meets demand.